This study aimed to assess the safety and reproducibility of cell therapy for its use in clinical practice. We performed immunophenotypic characterization of equine bone marrow-derived mesenchymal stromal cells (BMMSCs) by flow cytometry using CD90, CD19, CD14, CD105, CD45, and HLA-DR markers (n = 4); GTG banding cytogenetic analysis (n = 3); and microbiological quality control (n = 4). The immunomodulatory potentials of BMMSCs (n = 4) and its conditioned medium (CM, n = 3) were investigated by in vitro lymphocyte inhibition assay using phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMCs). BMMSCs populations isolated from all animals showed high expression of CD90 and CD105, and low expression of CD19, CD4, CD45, and HLA-DR. Of the 60 metaphases analyzed, 5% presented aneuploidy on random chromosomes and no contamination was found based on microbiological analyses. Both treatments significantly inhibited lymphocyte proliferation (> 50%), compared with PHA-stimulated PBMCs (p < 0.0001). These promising results for BMMSCs and CM justify their potential as a therapeutic approach for inflammatory diseases. The techniques used in this study were effective in assessing the quality and determining the minimum criteria for the clinical use of BMMSCs in veterinary medicine.

这项研究旨在评估细胞疗法在临床实践中的安全性和可重复性。我们使用CD90，CD19，CD14，CD105，CD45和HLA-DR标记通过流式细胞术对马骨髓间充质基质细胞（BMMSC）进行了免疫表型鉴定（n  = 4）；GTG条带细胞遗传学分析（n  = 3）；和微生物质量控制（n  = 4）。的BMMSCs（的免疫调节电位Ñ  = 4）和它的条件培养基（CM，Ñ  = 3）通过研究在体外使用植物血凝素（PHA）刺激的外周血单核细胞（PBMC）进行淋巴细胞抑制测定。从所有动物中分离出的BMMSC群体显示CD90和CD105高表达，而CD19，CD4，CD45和HLA-DR则低表达。在所分析的60个中期中，有5％在随机染色体上呈​​非整倍性，并且根据微生物学分析未发现污染。与PHA刺激的PBMC相比，两种治疗均显着抑制淋巴细胞增殖（> 50％）（p  <0.0001）。BMMSC和CM的这些有希望的结果证明了它们作为炎症性疾病治疗方法的潜力。本研究中使用的技术可有效评估BMMSC在兽药中的临床应用质量并确定最低标准。